Search

Herein, we report the design and crystal growth of the network of K2H2mpba (1) [H4mpba = N,N′-1,3-phenylenebis(oxamic acid)], which exhibits the quite unusual (6,12)-connected alb topology. The characterization of 1 shows the following features: (i) the presence of deprotonated H2mpba2− moieties, (ii) thermal stability up to approximately 300 °C, and (iii) H2mpba2− acting as a 12-c molecular building block (MBB) and occupying the vertices of the double six-membered ring "d6R". These rings combine with potassium ions, which fill the vertices of a trigonal prism. A discussion is provided on the role played by the type of metal centre (Mn+, M = Mn, Ni, Co, Cu) and countercation [tetrabutylammonium (TBA+) or tetraethylammonium (TEA+)] in a series of structurally characterized Mn+–H2mpba2− systems described in the literature. [ABSTRACT FROM AUTHOR]

Graphical abstract Highlights • Click Chemistry is the key step for obtaining 1,4 disubstituted-1,2,3-triazoles. • Compounds 9d and 10a presented higher potential antitumoral in glioblastoma cells. • Methylenoxy moiety is important for the pharmacological activity. • Compound 9d had the structural elucidation by single crystal X-ray diffraction. Abstract A new series of 1,4-disubstituted-1,2,3-triazole derivatives were synthesized through the copper-catalyzed azide-alkyne 1,3-dipolar cycloaddition (Click chemistry) and their inhibitory activities were evaluated against different human glioblastoma (GBM) cell lines, including highly drug-resistant human cell lines GBM02, GBM95. The most effective compounds were 9d, containing the methylenoxy moiety linked to triazole and the tosyl-hydrazone group, and the symmetrical bis-triazole 10a , also containing methylenoxy moiety linked to triazole. Single crystal X-ray diffraction analysis was employed for structural elucidation of compound 9d. In silico analyses of physicochemical, pharmacokinetic, and toxicological properties suggest that compounds 8a, 8b, 8c, 9d , and 10a are potential candidates for central nervous system-acting drugs. [ABSTRACT FROM AUTHOR]